Upcoming first-line chemotherapy for HER2-negative gastric cancer in Japan: which patients benefit from immunotherapy?

被引：4
|
作者：
Takahari, Daisuke [1 ]
Chin, Keisho [1 ]
Yamaguchi, Kensei [1 ]
机构：
[1] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Gastroenterol, Tokyo, Japan
来源：
FUTURE ONCOLOGY | 2020年 / 16卷 / 24期
关键词：
first-line chemotherapy; gastric cancer; pembrolizumab monotherapy; TAS-118 plus oxaliplatin; SOL; DOUBLE-BLIND; PHASE-III; CISPLATIN; NIVOLUMAB; S-1;
D O I：
10.2217/fon-2020-0421
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1797 / 1799
页数：3
相关论文
共 50 条
  • [21] Eribulin improved the overall survival from the initiation of first-line chemotherapy for HER2-negative advanced breast cancer: a multicenter retrospective study
    Nakamoto, Shogo
    Watanabe, Junichiro
    Ohtani, Shoichiro
    Morita, Satoshi
    Ikeda, Masahiko
    BMC CANCER, 2022, 22 (01)
  • [22] The full management from first-line to third-line treatments in patients with Her-2-negative advanced gastric cancer
    Chang, Chunxiao
    Pei, Yanqing
    Xu, Jun
    Zhang, Wenyu
    Zhang, Jianbo
    Shi, Shengbin
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [23] An estimation of the population survival benefit of first-line chemotherapy and immunotherapy for breast cancer
    Delaney, G. P.
    Do, V.
    Ng, W.
    Barton, M. B.
    CANCER RESEARCH, 2017, 77
  • [24] HER2-negative metastatic breast cancer patients receiving first-line docetaxel: Survival data and prognostic factors
    Deblock, M.
    Esterni, B.
    Tarpin, C.
    Charaffe-Jauffret, E.
    Extra, J. M.
    Viens, P.
    Goncalves, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [25] RE: A real-world survey on expensive drugs used as first-line chemotherapy in patients with HER2-negative unresectable advanced/recurrent gastric cancer in the stomach cancer study group of the Japan clinical oncology group
    Daungsupawong, Hinpetch
    Wiwanitkit, Viroj
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2024, 55 (01) : 87 - 88
  • [26] A prognostic factor index for overall survival in patients receiving first-line chemotherapy for HER2-negative advanced breast cancer: An analysis of the ATHENA trial
    Llombart-Cussac, Antonio
    Pivot, Xavier
    Biganzoli, Laura
    Cortes-Funes, Hernan
    Pritchard, Kathleen I.
    Pierga, Jean-Yves
    Smith, Ian
    Thomssen, Christoph
    Srock, Stefanie
    Sampayo, Miguel
    Cortes, Javier
    BREAST, 2014, 23 (05): : 656 - 662
  • [27] Bevacizumab Combined with Docetaxel or Paclitaxel as First-line Treatment of HER2-negative Metastatic Breast Cancer
    Tiainen, Leena
    Tanner, Minna
    Lahdenpera, Outi
    Vihinen, Pia
    Jukkola, Arja
    Karihtala, Peeter
    Paunu, Niina
    Huttunen, Teppo
    Kellokumpu-Lehtinen, Pirkko-Liisa
    ANTICANCER RESEARCH, 2016, 36 (12) : 6431 - 6438
  • [28] First-line rilvegostomig (rilve) plus chemotherapy (CTx) in patients (pts) with HER2-negative (HER2-) locally advanced unresectable or metastatic gastric cancers: First report of GEMINI-Gastric sub study 2
    Herrero, F. Rivera
    Oh, D-Y.
    Shitara, K.
    Chen, J-S.
    Jiang, J.
    Liu, S.
    Dong, Z.
    Zhu, Q.
    Zhang, X.
    Umiker, B.
    Kumar, R.
    Rha, S. Y.
    Shen, L.
    ANNALS OF ONCOLOGY, 2024, 35 : S887 - S887
  • [29] Vinorelbine Plus Gemcitabine or Cisplatin as First-line Treatment of HER2-negative Advanced Breast Cancer
    He, Kewen
    Wang, Xinzhao
    Guan, Xiyun
    Yu, Qian
    Ma, Qinghua
    Liu, Zhaoyun
    Yu, Zhiyong
    ANTICANCER RESEARCH, 2017, 37 (10) : 5647 - 5653
  • [30] Trastuzumab and first-line taxane chemotherapy in metastatic breast cancer patients with a HER2-negative tumor and HER2-positive circulating tumor cells: a phase II trial
    Noortje Verschoor
    Manouk K. Bos
    Ingeborg E. de Kruijff
    Mai N. Van
    Jaco Kraan
    Jan C. Drooger
    Johanna M. Zuetenhorst
    Saskia M. Wilting
    Stefan Sleijfer
    Agnes Jager
    John W. M. Martens
    Breast Cancer Research and Treatment, 2024, 205 : 87 - 95
12345